WebORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureu s (including methicillin-susceptible [MSSA] and -resistant [MRSA] … WebOct 5, 2016 · A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Actual Study Start Date : January 2024: Actual Primary Completion Date : June …
Kimyrsa, Orbactiv (oritavancin) dosing, indications, interactions ...
WebRefer to the ORBACTIV prescribing information for relevant information of the other oritavancin product. KIMYRSA is intended for intravenous infusion, only after reconstitution and dilution. One KIMYRSA 1,200 mg single-dose vial needs to be reconstituted and diluted to prepare a single 1,200 mg intravenous dose. Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin. The U.S. Food and Drug Administration (FDA) and … See more Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It … See more Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as Clostridium difficile , Clostridium perfringens See more Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005. In December 2008, the U.S. Food and Drug Administration (FDA) declined to approve oritavancin without … See more In 2003, results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of acute bacterial skin and skin-structure infections See more • "Oritavancin". Drug Information Portal. U.S. National Library of Medicine. See more bioglycols and services ltda
Medical Information Orbactiv® (oritavancin) for injection
WebAug 7, 2014 · ORBACTIV approval is based on the results of the SOLO I and SOLO II clinical studies which were randomized, double-blind, multicenter trials that evaluated a single 1200 mg IV dose of ORBACTIV for ... WebFeb 22, 2024 · Orbactiv IV is a prescription medicine used to treat the symptoms of Acute Bacterial Skin and Skin Structure Infections. Orbactiv IV may be used alone or with other medications. Orbactiv IV belongs to a class of drugs called Glycopeptides. It is not known if Orbactiv IV is safe and effective in children younger than 18 years of age. WebHow to use Orbactiv Vial This medication is given by a health care professional as a single dose. Depending on your product, this medication is injected slowly into a vein over 1 or 3 … daily aspirations